Clinical Trial Update: A Trial to Evaluate the Safety and Immune Response of an Investigational Pneumococcal Vaccine in Adults 50 To 64 Years of Age [Phase 1]

View source ↗

Summary

This update describes a Phase 1 clinical trial evaluating the safety and immune response of an investigational pneumococcal vaccine in adults aged 50 to 64.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Infections
• Pneumonia

Drugs mentioned

• Investigational pneumococcal vaccine (GSK)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Pneumonia, Bacterial | Phase 1 | Status: ACTIVE_NOT_RECRUITING